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A B S T R A C T   
Introduction: Osteosarcoma is a common bone malignancy in patients of all ages. Surgical and chemotherapy 
interventions fail to shrink tumor growth and metastasis. The development of efficient patient-specific thera-
peutic strategies for osteosarcoma is of great interest in tissue engineering and personalized medicine. The 
present manuscript aimed to review the advancements in tissue engineering and personalized medicine strategies 
to overcome osteosarcoma and the relevant biological aspects as well as the current tumor models in vitro and in 
vivo. 
Results: Tissue engineering and personalized medicine contribute to gene/cell engineering and cell-based ther-
apies specific to genomic and proteomic profiles of individual patients to improve the current treatment options. 
Also, tissue engineering scaffolds provide physical support to missing bones, could trap cancer cells and deliver 
immune cells. Taken together, these strategies suppress tumor growth, angiogenic potential, and the subsequent 
metastasis as well as elicit desirable immune responses against tumor mass. 
Discussion: Advanced and high-throughput gene and protein identification technologies have facilitated the 
recognition of genomic and proteomic profiles of patients to design and develop patient-specific treatments. The 
pre-clinical studies showed promising outcomes to inhibit tumor growth and invasion but controversial results 
compared to clinical investigations make the importance of more clinical reports inevitable. The experimental 
tumor models assist the evolution of effective treatments by understanding the mechanisms of tumor 
progression. 
Conclusion: Tissue engineering and personalized medicine strategies seem encouraging alternatives to conven-
tional therapies against osteosarcoma. Modeling the tumor microenvironment coupled with pre-clinical results 
give new intelligence into the translation of strategies into the clinic.   
Introduction 
Osteosarcoma is the most widespread bone primary malignancy that 
involves children, youth, and adolescents, and metastasis is diagnosed in 
20% of patients [1]. Common therapeutic strategies to treat osteosar-
coma account for surgical resection followed by chemotherapy regimens 
to prevent tumor metastasis [2]. However, chemotherapy-induced tox-
icities are still the main challenge to the applied chemotherapy treat-
ments [3]. It has been demonstrated that osteosarcoma emergence and 
progress are associated with genetic variations. The genetic variations 
and instabilities make the molecular mechanisms of osteosarcoma 
pathogenesis difficult to understand [4]. These challenges are of great 
interest to design and carry out patient-specialized investigations. 
Personalized medicine is an appearing field of medicine regarding the 
genetic and molecular aspects of diseases like cancer and enables re-
searchers to make decisions to predict, prevent, diagnose, and treat 
diseases [5]. Next-generation gene sequencing, morphogenomic (the 
combination of morphology and genomics), and morphoproteomic (the 
combination of morphology and proteomics) assays are efficient tech-
niques to facilitate the evolution of personalized medicine-based tar-
geted therapies [6]. Tissue engineering and regenerative medicine 
(TERM) is an interdisciplinary field of medicine, biomaterials, and cell 
biology contributing to the design and employment of strategies to 
restore the structure and function of damaged tissues [7]. The field of 
TERM introduces both in vitro and in vivo models and therapeutic stra-
tegies to surpass the current knowledge of osteosarcoma biology and 
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treatment efficacy. Herein, the overlapping areas of personalized med-
icine and tissue engineering were reviewed as well as the application of 
tissue engineering in personalized medicine in various directions were 
discussed. 
Osteosarcoma pharmacogenomics; definition and data sources 
The concept of pharmacogenomics results from the combination of 
two words ’pharmacology’ and ’genomics.’ It is a part of precision 
medicine and is defined as the use of genome-related technologies to 
understand how genetic composition influences the drug efficacy and 
toxicity [8]. The genomic-based drug administration is noteworthy 
because the drug response under the same therapy condition (drug type, 
dose, and treatment duration) differs among patients. Large-scale 
genomic and proteomic databases give valuable data on the whole 
genome, epigenome, and phenotype to predict the patient response to 
drugs and relevant activities. 
The use of gene sequencing, transcriptional, and computational (in 
silico) methodologies in preclinical and clinical studies are beneficial to 
develop and translate personalized drugs into the clinic [9-12]. More-
over, different theories are studied, offer organized roadmaps for 
designing projects, and eventually, novel drugs or therapeutic options 
are achieved. Comprehensively, pharmacogenomics research based on 
computer studies and database exploration is the currently introduced 
approach to generate novel therapies in precision medicine [11, 12]. 
It has been revealed that detected biomarkers in patients suffering 
from osteosarcoma could serve as promising markers in osteosarcoma 
pharmacogenomics. Studies on ATP-binding cassette transporter 1 
(ABCB1), dihydrofolate reductase (DHFR), solute carrier family 19 
member 1 (SLC19A1), human epidermal growth factor receptor 2 
(HER2) [8], circulating tumor suppressor microRNAs (miR326, 
miR125b, miR133b, miR206, miR152, miR95–3p, miR34b, miR195, 
miR223, miR497), oncogenic microRNAs (miR-17, miR21, miR-24, 
miR-25–3p, miR29a/b/c, miR143, miR196a/b, miR199a-3p, miR-221, 
miR236,), and long non-coding RNAs (TUG1, 91H, UCA1, ATB, 
MALAT-1) would be effective to predict tumor prognosis, therapy 
resistance, and survival [13]. 
Cell-based personalized therapeutic approaches against 
osteosarcoma 
The tissue engineering (TE) concept relies on the use of biomaterials, 
cells, and biomolecules, alone or in combination, to provide specific 
approaches to repair and regenerate damaged tissues or organs [14]. TE 
strategies are coupled with personalized medicine through cell therapy, 
cell engineering, and genetic manipulation procedures (Fig. 1). 
Cell-based strategies serve as the first aim of personalized medicine 
employed for both somatic and cancer cells. Differentiation therapy 
(inducing cancer cells into fully differentiated cell lineages) is beneficial 
to overcome osteosarcoma therapy resistance. Fasudil treatment 
induced the adipogenic differentiation of highly resistant osteosarcoma 
cells by remodeling the cytoskeleton arrangement and the blockage of 
the tumor growth and resistance [15]. Trabectedin prompted the ter-
minal differentiation of osteosarcoma cells into osteoblasts character-
ized by increased expression of RUNX2, reduced tumorigenicity, and 
increased population of CD8 T lymphocytes [16]. 
Genetic editing methods discuss two main issues of selecting 
appropriate gene targets and designing efficient gene delivery systems. 
VEGFA gene editing was conducted using a tumor-targeted lipopolymer 
delivery system carrying the CRISPR/Cas9 plasmids. The inhibition of 
the VEGFA gene led to reduced angiogenesis and tumor growth as well 
as suppressed the lung metastasis capacity of osteosarcoma cells [17]. 
GIT1, a target to osteosarcoma treatment recently introduced by Zhang 
et al. attributed to the angiogenesis and invasive potential of osteosar-
coma cells via activating hypoxia-inducible factor1α (HIF1α) and 
extracellular signal-regulated kinase (ERK1/2) pathways respectively 
[18]. The knockdown of PTBP1, an RNA-binding protein gives rise to 
higher levels of copper transporter 1 protein SLC31A1, responsible for 
drug influx and cisplatin sensitivity [19]. ALDH1B1 knockdown was 
associated with inhibited in vitro growth, migration, invasion, and 
induced cell cycle arrest at the G1 phase of osteosarcoma cells and 
repressed xenograft tumor growth [20]. siRNA nanocarriers of 
chitosan-folic acid efficiently transferred the astrocyte elevated gene-1 
(AEG-1) siRNA into the osteosarcoma cells followed by modulating 
matrix metalloproteinases 2/9 (MMP-2/9) and diminished tumor 
growth and metastasis [21]. 
Adoptive cell therapy (ACT), is a strategy to strengthen the immune 
cell activities by isolating autologous immune cells, making genetic 
manipulations, and subsequent reinfusion of genetically modified cells 
into the patient’s body to reach immune responses of interest [22]. A 
broad range of cell-based therapeutic studies focus on dendritic cells, 
antigen-presenting members of the immune system. Dendritic cell vac-
cines provide a remarkable antigen-specific immune response and 
anti-tumor effect against preclinical osteosarcoma models identified by 
enhanced cytotoxic T lymphocytes [23] and abolished regulatory T cells 
[24]. Invariant natural killer cells (iNK), a subpopulation of immune 
Fig. 1. Tissue engineering/personalized medicine contribution to advance anti-tumor strategies. Patient-specific cell therapies and genetic manipulation endow 
improved outcomes including tumor repression, inhibited invasion and angiogenesis, active immune responses, and higher sensitivity to current therapeu-
tic regimens. 
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cells with bifunctional properties of T-cells and NK cells specifically 
target osteosarcoma cells through CD1d- dependent cytotoxicity and 
intensify the chemotherapy-induced cell death [25]. 
Chimeric antigen receptor-engineered T-lymphocytes (CAR T-cells) 
are well-known engineered cell populations with two main manipulated 
entities of specific antibody recognition domain and T cell receptor 
(TCR) to recognize certain antigens followed by activating response 
signals from TCR [26]. Genetically engineered oncolytic viruses are used 
as immune response eliciting and cancer cell death mediators in a va-
riety of cancers include osteosarcoma [27]. Clinical CAR T-cell therapy 
against HER-2 positive osteosarcoma was found safe but the results 
showed that the CAR T-cell population failed to expand following the 
infusion [28]. In addition to immune cells, cancer cells can be geneti-
cally modified to express specific antigens that prevent them to escape 
and hide. These solutions could be accomplished by getting access to the 
genomic and proteomic profiles of the patient [29]. 
Tissue engineering strategies to overcome osteosarcoma 
progression 
Generally, tissue engineering strategies act to regress the tumor 
growth as well as heal the tumor site in three directions. First, TE scaf-
folds could are considered as defect filler constructs; When the osteo-
sarcoma tumor is removed from bone tissue, large defects remain in the 
tumor site. Herein, tissue-engineered products provide physical support 
to and fill the gap of missing bone [30, 31]. Given extensive studies 
conducted, several tissue-engineered products received the necessary 
licenses and have been commercialized for use in the clinic [32-35]. An 
example of personalized tissue-engineered products is 3D-printed tita-
nium implants with improved biomechanical properties that ameliorate 
the patient’s clinical outcome [36]. 
Second, TE scaffolds actively repress tumor growth and metastasis in 
several ways. Experimental investigations indicated that scaffolds 
implanted in the vicinity of the primary tumor strongly reduced the rate 
of metastasis from the primary tumor to tissues such as bone, lung, etc. A 
study on breast cancer biology evidenced that biomaterial scaffolds 
could modulate the tumor microenvironment, thereby immune cell se-
cretions and phenotypes shift in favor of tumor suppression [37]. 
Microporous polycaprolactone scaffolds could trap breast cancer cells 
and prevent them from metastasizing to the tissues resulting in impaired 
tumor recurrence and prolonged survival [38]. Also, biomaterials in-
crease the metabolism and migration of the host immune cells making 
them new candidates as adjuvants or therapeutic vaccines [39, 40]. In 
the third mechanism of anti-tumor action, scaffolds could carry a pop-
ulation of antigen-presenting cells and immune system modulators to 
intensify the immune system against cancerous tissue [38, 41]. 
Small biomolecules play a considerable role in restaining osteosar-
coma growth and invasion. TE scaffolds delivered vitamin C, not only 
diminished the proliferation of osteosarcoma cells but also stimulated 
osteogenic progression [42]. All-trans retinoic acid (ATRA) prohibited 
the polarization of tumor-associated macrophages (TAMs) into M2 
phenotype via inhibiting the IL-13/14 production and induced a nega-
tive effect on cancer cell migration [43]. Dihydroxycoumarins displayed 
a dual direct and indirect function of G1 cell cycle arrest and suppression 
of M2 macrophage differentiation respectively [44]. 
The next generation of TE products with progressed efficiency in 
personalized medicine is necessary to develop according to the geno-
typic and phenotypic profiles of patients. This leads to a variety of 
products in different groups prepared based on age, sex, race, and 
specialized structure and function of interest for each person. 
Personalized osteosarcoma models; in vitro and in vivo evidence 
In vitro models 
2D culture: Monoculture models (monolayer, transwell, conditioned 
medium) are regarded as the first applied models in bone cancer 
research. Osteosarcoma cultures are usually obtained from both normal 
and cancerous sources ((Fig. 2). Genetically modified mesenchymal 
stem cells (MSCs) with retinoblastoma (Rb) knockdown and c-Myc 
overexpression resulted in osteosarcoma formation associated with 
enhanced cell growth and sphere formation in vitro [45]. It is suggested 
that the source of MSCs and osteogenic commitment are key factors to 
succeed in the formation of osteosarcoma models. For example, 
P53/retinoblastoma deficient bone marrow-derived MSCs undergoing 
osteogenic commitment exhibit a greater rate of bone sarcomas than 
undifferentiated MSCs or osteogenic precursors derived from adipose 
tissue MSCs [46]. Although, some evidence concludes that interfering 
with Trp53 and Rb1 expression successfully induces MSCs, 
pre-osteoblasts, and fully differentiated osteoblasts into osteosarcoma 
cells [47]. Some cancer-related genetic disorders provide suitable 
personalized osteosarcoma models. Li-Fraumeni syndrome (LFS) is an 
autosomal dominant inherited disease that makes patients susceptible to 
different types of cancers including osteosarcoma. Induced pluripotent 
stem cells (iPSCs) from LFS patients that were differentiated into oste-
oblasts showed impaired expression of P53 and H19 leading to tumor 
recurrence [48]. Moreover, the increased expression of secreted 
frizzled-related protein 2 in LFS derived iPSCs promoted osteosarco-
magenesis via prompting FOXM1 and CYR61oncogens [49]. 
3D culture: Despite the extended studies on osteosarcoma biology 
and treatment, 2D tumor models are unable to depict a comprehensive 
explanation of the physico/chemical state of the tumor microenviron-
ment, cell-cell, cell-ECM interactions, drug resistance, and tumor het-
erogeneity [50]. So, the presentation of 3D models that mimic the tumor 
microenvironment seems inevitable. 3D tumor models are categorized 
into scaffold-based, cell-based, and mixed models (Fig. 2). In 
scaffold-based models, synthetic and natural materials such as bone 
extracellular matrix [51], collagen [52], silk [53], poly-caprolactone 
(PCL) [54], poly(lactic acid-co-glycolic acid) (PLGA) [55], as solid 
scaffolds or hydrogels are utilized in bone cancer modeling. 
Tumor cell spheroids known as 3D cell-based models could be 
generated using both static methods including hanging drop [56] and 
dynamic conditions such as spinner flasks, stirred-tank cultures, and 
bioreactors [57]. Osteosarcoma spheroids have a stronger drug resis-
tance potential than monolayer cultures attributed to the elevated 
expression of cathepsin D [58]. The cell/scaffold complexes as newly 
introduced artificial tumor niches that open new insights into the 
interaction of osteosarcoma cells with their microenvironment. The 
combination of adipose-derived mesenchymal stem cells (ADMSCs) and 
gellan gum (GG)-silk fibroin scaffolds provide a micro-niche with 
appropriate stiffness to increase the proliferation, spheroid formation, 
and osteosarcoma- related gene expression of saos-2 cells [59]. Hydrogel 
microspheres of hyaluronan/gelatin presented a useful platform for 
bone metastasis of prostate cancer [60]. 
In vivo models 
Patient-derived osteosarcoma xenografts are common models to 
evaluate the development of bone cancer and the underlying molecular 
mechanisms. Specimens are obtained from patients suffering from os-
teosarcoma, subcutaneously transplanted into immunodeficient animals 
followed by the re-transplantation of newly formed tumors into new 
hosts. Molecular and histological assessments of implanted tumors aid 
researchers to uncover key aspects of osteosarcoma formation and 
progression [61]. The in vivo humanized osteosarcoma model was 
generated from implantable 3D-printed PCL scaffolds in combination 
with hydrogel embedded human umbilical cord vein endothelial cells 
and human osteosarcoma cells [54]. 
Personalized combination therapies against osteosarcoma 
The common therapeutic options for patients that suffer from 
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osteosarcoma are surgical removal and subsequent chemotherapies to 
suppress the metastatic progression of the tumor. The common chemo-
therapy regimens include a combination of cisplatin, doxorubicin, and 
high-dose methotrexate with leucovorin rescue (MAP) [62]. Long-term 
consequences such as nephrotoxicity and cardiotoxicity followed by 
MAP administration makes scientists seek new alternatives [3]. Some 
agents have been presented as neoadjuvant such as high-dose ifosfamide 
and etoposide(I/E) [63] and interferon alfa-2b [64] but they lack sig-
nificant therapeutic efficiency. 
Personalized chemotherapy regimens enable researchers to under-
stand the mechanisms of genome-related drug metabolism and resis-
tance, osteosarcoma-related gene mutations, and mapping the gene 
correlations [65]. These findings along with optimized tissue 
engineering-based drug delivery strategies give new imagination into 
the design and development of more efficient personalized treatments. A 
promising strategy against osteosarcoma is encapsulating Muramyl tri-
peptide phosphatidylethanolamine (MTP-PE) into liposomes to actuate 
monocytes and macrophages [66]. A combination therapy based on 
MAP-MTP-PE has been elucidated to upgrade the free survival and 
overall survival of patients [67]. Immunotherapy strategies based on 
PD1/PDL1 communication have been found to improve patient survival 
and diminished metastasis in PDL1 expressing osteosarcoma cells [68]. 
Endoglin-targeting antibodies conjugated with nigrin-b A chain and 
cytolysin successfully inhibited the proliferation of Ewing sarcoma cells 
and repressed the patient-derived tumor growth in vivo [69]. 
Co-administration of eribulin and temozolomide to patient-derived 
orthotopic xenograft (PDOX) model suppressed the tumor growth and 
resistance to a variety of agents such as doxorubicin, sunitinib, and 
pazopanib [70]. A combination of PARP inhibitor, olaparib, and doxo-
rubicin inhibited the osteosarcoma cell growth and induced apoptosis 
[71]. Co-treatment of therapeutic agents with cells such as oncolytic 
viruses and cisplatin [72], dendritic cells with antibodies of trans-
forming growth factor-β (TGF-β) [73], and glucocorticoid-induced 
tumor necrosis factor receptor (GITR) [24] was accompanied by an 
enhanced rate of autophagy in vitro and suppressed lung metastasis in 
vivo. 
Discussion and conclusion 
Personalized medicine and tissue engineering are two major fields 
concerning bone cancer research and treatment aim in the development 
of advanced targeted strategies to compensate for the present thera-
peutic options and defeat tumor growth and metastasis. Targeted cancer 
therapies require the identification of genetic alterations of individual 
patients as well as the effect of genomic variations on the patient 
response to treatment should be considered. High-throughput technol-
ogies like next-generation sequencing enrich the current knowledge to 
achieve an efficient therapy. Comprehensive preclinical researches and 
clinical trials are needed to ensure the efficacy and feasibility of 
currently developed strategies. The common spots in personalized 
medicine and tissue engineering are gene engineering, cell engineering, 
and cell-based therapies to suppress cancer cell metabolism, growth, and 
invasion. Immune cells play a prominent role in the modulation of the 
tumor microenvironment. Tissue engineering scaffolds not only support 
the structure of tumor-damaged bone but also prohibit the cancer cell 
growth and metastasis via trapping cancer cells and regulating tumor 
niche status as well as deliver immune cells to the tumor site to take 
favorable immune responses. Small biomolecules own the same effects 
toward tumor repression. Although the conventional chemotherapy 
regimens have been combined with immunotherapy agents such as 
interleukin-2 (IL-2) [74] and IGF-1R antibodies [75], no significant 
clinical outcome was not found in patients. Clinical studies on dendritic 
cell-based vaccines did not face the same success as preclinical ones 
[76]. Therefore, it seems that the controversial results of preclinical and 
clinical examinations are challenging issues in front of clinical trans-
lation of personalized medicine and tissue engineering procedures. 
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